New strategies against drug resistance to herpes simplex virus - PubMed (original) (raw)

Review

New strategies against drug resistance to herpes simplex virus

Yu-Chen Jiang et al. Int J Oral Sci. 2016.

Abstract

Herpes simplex virus (HSV), a member of the Herpesviridae family, is a significant human pathogen that results in mucocutaneous lesions in the oral cavity or genital infections. Acyclovir (ACV) and related nucleoside analogues can successfully treat HSV infections, but the emergence of drug resistance to ACV has created a barrier for the treatment of HSV infections, especially in immunocompromised patients. There is an urgent need to explore new and effective tactics to circumvent drug resistance to HSV. This review summarises the current strategies in the development of new targets (the DNA helicase/primase (H/P) complex), new types of molecules (nature products) and new antiviral mechanisms (lethal mutagenesis of Janus-type nucleosides) to fight the drug resistance of HSV.

PubMed Disclaimer

Figures

Figure 1

The anti-HSV mechanism of ACV. ACV, acyclovir; HSV, herpes simplex virus.

Figure 2

The chemical structures of two potent HPI active compounds against HSV. HPI, helicase-primase inhibitor; HSV, herpes simplex virus.

Figure 3

The lethal mutagenesis mechanism of ribavirin. The ribavirin cis conformer can pair with uridine by mimicking adenosine, and the trans conformer can pair with cytidine by mimicking guanosine.

Figure 4

The potential mutagenic molecule. Janus nucleoside analogues (for example, J-GC) can pair with guanosine and cytidine by rotating around the glycosyl bond. J-GC, Janus-type pyrimido[4,5-d]pyrimidine guanosine–cytosine.

Similar articles

• Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation.
  Iino T, Gondo H, Ohno Y, Minagawa H, Iwasaki H, Maruyama T, Nakashima H, Niho Y. Iino T, et al. Bone Marrow Transplant. 1996 Dec;18(6):1185-8. Bone Marrow Transplant. 1996. PMID: 8971394
• Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients.
  Levin MJ, Bacon TH, Leary JJ. Levin MJ, et al. Clin Infect Dis. 2004 Nov 1;39 Suppl 5:S248-57. doi: 10.1086/422364. Clin Infect Dis. 2004. PMID: 15494896 Review.
• A new promising candidate to overcome drug resistant herpes simplex virus infections.
  Zinser E, Krawczyk A, Mühl-Zürbes P, Aufderhorst U, Draßner C, Stich L, Zaja M, Strobl S, Steinkasserer A, Heilingloh CS. Zinser E, et al. Antiviral Res. 2018 Jan;149:202-210. doi: 10.1016/j.antiviral.2017.11.012. Epub 2017 Nov 15. Antiviral Res. 2018. PMID: 29155164
• Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.
  Arduino PG, Porter SR. Arduino PG, et al. Oral Dis. 2006 May;12(3):254-70. doi: 10.1111/j.1601-0825.2006.01202.x. Oral Dis. 2006. PMID: 16700734 Review.
• Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials.
  Sarisky RT, Bacon TH, Boon RJ, Duffy KE, Esser KM, Leary J, Locke LA, Nguyen TT, Quail MR, Saltzman R. Sarisky RT, et al. Arch Virol. 2003 Sep;148(9):1757-69. doi: 10.1007/s00705-003-0124-7. Arch Virol. 2003. PMID: 14505088 Clinical Trial.

Cited by

• HerpDock: A GUI-based gateway to HSV-1 molecular docking insights.
  Singh SK, Kapoor D, Shukla D. Singh SK, et al. Comput Struct Biotechnol J. 2024 Oct 13;23:3692-3701. doi: 10.1016/j.csbj.2024.10.013. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 39507821 Free PMC article.
• Recent Advances in the Synthesis of Acyclic Nucleosides and Their Therapeutic Applications.
  Kumar S, Arora A, Chaudhary R, Kumar R, Len C, Mukherjee M, Singh BK, Parmar VS. Kumar S, et al. Top Curr Chem (Cham). 2024 Oct 23;382(4):34. doi: 10.1007/s41061-024-00476-7. Top Curr Chem (Cham). 2024. PMID: 39441318 Review.
• Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy.
  Mariotti M, Giacon N, Lo Cascio E, Cacaci M, Picchietti S, Di Vito M, Sanguinetti M, Arcovito A, Bugli F. Mariotti M, et al. Pharmaceutics. 2024 Sep 18;16(9):1218. doi: 10.3390/pharmaceutics16091218. Pharmaceutics. 2024. PMID: 39339254 Free PMC article.
• Antiviral activity of temporin-1CEb analogues against gingival infection with herpes simplex virus type 1.
  Golda A, Kosikowska-Adamus P, Wadowska M, Dobosz E, Potempa J, Koziel J. Golda A, et al. Front Oral Health. 2024 Jun 17;5:1430077. doi: 10.3389/froh.2024.1430077. eCollection 2024. Front Oral Health. 2024. PMID: 38953010 Free PMC article.

References

1. 1. Howard CR, Fletcher NF. Emerging virus diseases: can we ever expect the unexpected? Emerg Microbes Infect 2012; 1 (12): e46. - PMC - PubMed
2. 1. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002; 5 (2): 88–114. - PubMed
3. 1. Wilson SS, Fakioglu E, Herold BC. Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther 2009; 7 (5): 559–568. - PMC - PubMed
4. 1. Markus A, Grigoryan S, Sloutskin A et al. Varicella-zoster virus (VZV) infection of neurons derived from human embryonic stem cells: direct demonstration of axonal infection, transport of VZV, and productive neuronal infection. J Virol 2011; 85 (13): 6220–6233. - PMC - PubMed
5. 1. Burrel S, Ait-Arkoub Z, Voujon D et al. Molecular characterization of herpes simplex virus 2 strains by analysis of microsatellite polymorphism. J Clin Microbiol 2013; 51 (11): 3616–3623. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal